ライフサイエンスコーパス: weight loss

1 nt to chemotherapy-induced anorexia and body weight loss.

2 th muscle insulin sensitivity, improved with weight loss.

3 nts and that this is clearly associated with weight loss.

4 nt and biological adaptations that accompany weight loss.

5 eviews intensive lifestyle interventions for weight loss.

6 nts from a behavioural intervention aimed at weight loss.

7 BC xenograft models without significant body weight loss.

8 ampus promoted a negative energy balance and weight loss.

9 o induce appetite suppression and may induce weight loss.

10 reduction in muscle and bone mass induced by weight loss.

11 zed fatigue, anorexia, chronic diarrhea, and weight loss.

12 inally obese men but became comparable after weight loss.

13 ojections for cisplatin-induced anorexia and weight loss.

14 cal or not is independent of the duration of weight loss.

15 HFD is highly dynamic and can be reversed by weight loss.

16 to dehydration, poor nutritional intake, and weight loss.

17 and phloridzin also resulted in significant weight loss.

18 y after bariatric surgery predicts long-term weight loss.

19 performance, accompanied by progressive body weight loss.

20 ipitation were significantly associated with weight loss.

21 ppress food intake provides a new target for weight loss.

22 ments for, chemotherapy-induced anorexia and weight loss.

23 mediates cisplatin-induced anorexia and body weight loss.

24 igated how BAmF evolves with the duration of weight loss.

25 ements marketed as "100% natural" to enhance weight loss.

26 le sclerosis, reducing clinical severity and weight loss.

27 fat metabolism and is a validated target for weight loss.

28 ffects of weather on factors associated with weight loss.

29 and food intake, and exacerbated LP-induced weight loss.

30 storage in inert adipose tissue during rapid weight loss.

31 quality-of-life improvements associated with weight loss.

32 upporting behavioral changes to promote a 5% weight loss.

33 anscriptional program that may persist after weight loss.

34 explained by smoking and disease-associated weight loss.

35 highlighting the complexity of postoperative weight loss.

36 rates of progression were lower with greater weight loss.

37 characterized by self-starvation and extreme weight loss.

38 ver enzymes, abdominal pain, and significant weight loss.

39 oves glucose tolerance independently of body weight loss.

40 pensated for the decrease in fat mass during weight loss.

41 even smaller in the group with more than 10% weight loss (1.0; 95% CI: 0.6, 1.4; P = .001) when compa

42 tigue (70%), anorexia (64%), vomiting (43%), weight loss (32%), and diarrhea (32%), which were primar

43 hy (71.4%), respiratory symptoms (66.7%) and weight loss (49.2%).

44 To evaluate effect on comorbid disease and weight loss 5 years after Roux-en-Y gastric bypass (RYGB

45 Among those with >/=10% initial weight loss, 7 of 28 comparisons in Look AHEAD and 13 of

46 [37%] of 41), hyperglycaemia (17 [41%]), and weight loss (8 [20%]); those with a suspected associatio

47 yline group and paresthesia (31% vs. 8%) and weight loss (8% vs. 0%) in the topiramate group.

48 m screening (fever, cough, night sweats, and weight loss), a rapid test detecting mycobacterial lipoa

49 These recommendations can include weight loss, adequate hydration, avoidance of excessive

50 A 10-kg achieved weight loss after 1 year was related to a hazard ratio f

51 Child weight loss after 6 months was -0.25 BMI z scores in bot

52 PP; n = 613) participants with >/=3% initial weight loss after lifestyle interventions and 4-y follow

53 e which lack endothelial Piezo1 and there is weight loss after sustained activity.

54 Both antibodies reduced mortality, weight loss, airway inflammation, and pulmonary viral lo

55 Moderate weight loss alone inadequately reflects the significant

56 surpass the expected improvement due to body weight loss alone.

57 urgery for complications of surgery or rapid weight loss and 58 (72%) showed some type of nutritional

58 (control) consumption and determined whether weight loss and acquired behaviors persisted after the s

59 Bariatric surgery results in notable weight loss and alleviates hyperglycemia in patients wit

60 Coatings decreased weight loss and also the greatest juice percent was in c

61 Esophagectomy is associated with significant weight loss and catabolism, and negatively impacts quali

62 This was associated with weight loss and changes in lung physiology consistent wi

63 , lack of PD-ligands did not result in early weight loss and colon GVHD comparable to that induced by

64 after 8days of storage by reduction in total weight loss and decay, SSC/TA ratio (also at 16days), an

65 rved a graded association between increasing weight loss and decreasing risk of heart failure.

66 ncreased life span, characterized by delayed weight loss and diminished motor decline.

67 This study showed long-term durability of weight loss and effective remission and prevention of ty

68 ented with acute onset jaundice, significant weight loss and elevated liver enzymes with clinico-radi

69 A plaque-purified MERSMA clone caused weight loss and fatal infection.

70 the realistic challenges of maintaining 100% weight loss and flexible application in populations with

71 umber of responders at 24 h, despite greater weight loss and fluid loss.

72 PINTA745 reduced body weight loss and improved body weight recovery after cere

73 hyperintensity despite inducing significant weight loss and improvement of peripheral insulin sensit

74 t-management programme would achieve greater weight loss and improvements in a range of health outcom

75 Whey protein promotes weight loss and improves diabetic control, however, less

76 ammatory colon cancer, augmented DSS-induced weight loss and increased tumor multiplicity, size, and

77 achexia affects many cancer patients causing weight loss and increasing mortality.

78 n of only the KLK5-treated virus resulted in weight loss and lethal outcomes.

79 Moreover, elevated O-GlcNAc levels promoted weight loss and lowered respiration in mice and skewed t

80 t subtypes of influenza viruses by lessening weight loss and lowering viral loads.

81 Rapid weight loss and malabsorption after bariatric surgery in

82 Modified fasting regimens appear to promote weight loss and may improve metabolic health.

83 +)-JQ1 protects tumor-bearing mice from body weight loss and muscle and adipose tissue wasting.

84 A 52-week programme produces greater weight loss and other clinical benefits than a 12-week p

85 the enhanced antimicrobial treatment reduced weight loss and pitting corrosion.

86 tissue colonization, along with ameliorated weight loss and prolonged survival, depends on microbiot

87 th, with the highest risk in those with both weight loss and reduced strength (HR: 3.77; 95% CI: 2.54

88 Egfr(f/f) mice given DSS protected them from weight loss and restored epithelial proliferation and ST

89 nt-based treatment was as effective on child weight loss and several secondary outcomes (parent weigh

90 Bariatric surgery has been recommended for weight loss and to improve asthma control; however, the

91 GPD1L was found to be upregulated during weight loss and weight maintenance induced by low calori

92 in Rag1(-/-) mice, the mice showed dramatic weight loss and ZIKV infection in the brain and testes.

93 77 participants; P = 0.35).After a mean 10% weight-loss and 1-y maintenance, additional use of daily

94 0 virus infection of ferrets caused variable weight loss, and all 20 viruses replicated throughout th

95 ting with abdominal pain, chronic diarrhoea, weight loss, and fatigue.

96 C coating minimized chlorophyll degradation, weight loss, and firmness of bananas while ensuring the

97 s evidenced by reduced survival, more severe weight loss, and increased histopathologic damage compar

98 status score 1 or 2, systemic inflammation, weight loss, and other disease-related morbidities assoc

99 the PFS model also included marital status, weight loss, and p16 x Zubrod interaction.

100 dria, glial cell activation, muscle atrophy, weight loss, and reduced survival.

101 rine output, enhanced plasma volume, reduced weight loss, and substantially improved overall outcomes

102 In humans, elevated GDF15 correlates with weight loss, and the administration of GDF15 to mice wit

103 affect changes in glucose metabolism during weight loss, and this effect is dependent on dietary fat

104 Survival, weight loss, and viral titers were assessed over a 14-da

105 gly not the 5-HT2C, receptor is critical for weight loss, anorexia, and fat mass reduction induced by

106 oriasis and obesity are strongly linked, and weight loss appears to improve psoriasis symptoms and se

107 INTERPRETATION: Effects of liraglutide on weight loss are associated with delay in gastric emptyin

108 Early satiety and weight loss are common after esophagectomy, but the path

109 ty or dietary interventions toward efficient weight loss, are missing.

110 rative differences in nutrient intake and/or weight loss as well as differences in the secretion of h

111 nd chronic stress and were protected against weight loss associated with chronic stress.

112 Body weight loss at 6 weeks and 3 months postoperatively amon

113 Secondary outcomes included weight loss at weeks 5 and 16, satiation (volume to full

114 rm of NPC1 disease which is characterized by weight loss, ataxia, increased cholesterol storage, loss

115 ultifactorial syndrome characterized by body weight loss, atrophy of adipose tissue (AT) and systemic

116 Weight loss before transplantation may be beneficial, bu

117 Secondary outcomes were parent weight loss (BMI), child and parent energy intake, child

118 The primary outcome measure was child weight loss (body mass index [BMI] and BMI z score) at 6

119 hese changes were accompanied by diminishing weight loss, bone mineral density (BMD), trabecular thic

120 ment increases energy expenditure and causes weight loss, but is contraindicated for obesity treatmen

121 Despite initial success, weight loss by calorie restriction (CR) often fails beca

122 around the world, and although even moderate weight loss can improve metabolic health, reduced calori

123 However, weight loss can lead to physiological adaptations that p

124 dney), resulted in rapid lethality marked by weight loss, changes in nutritional as well as blood par

125 d the effect of these 2 treatments on parent weight loss, child and parent dietary intake, child and

126 Weight loss combined with sarcopenia presented the great

127 Both groups were compared for weight loss, comorbidities, quality of life, and complic

128 vention group produced greater mean 12-month weight loss compared with the standard care group (3.2 k

129 ular function have been performed without no-weight loss control groups and in individuals with obesi

130 4.9) were given hypocaloric diets to promote weight loss corresponding to 10-15% of initial body weig

131 TSO treatment prevented the DSS induced weight loss, delayed the onset of DSS induced symptoms b

132 etes (T2D) remission through a succession of weight loss-dependent and -independent mechanisms.

133 eatment-related adverse events were fatigue, weight loss, diarrhea, palmar-plantar erythrodysesthesia

134 Although mean weight loss did not reach the targeted 5%, the mean loss

135 starch metabolism influences the response to weight-loss dietary intervention.

136 ary protein) may impact the effectiveness of weight loss diets.

137 To compare 2 standardized weight-loss diets among adolescents with overweight or o

138 ght maintenance "regaining </=25% of initial weight loss during maintenance" is a preferred definitio

139 maintained higher fruit firmness and reduced weight loss during storage.

140 of meteorological conditions on intentional weight loss efforts on a global scale (not only on a loc

141 4-m walk time, grip strength, self-reported weight loss, exhaustion, and low activity.

142 by >/=3 frailty-related phenotype criteria (weight loss, exhaustion, low activity, slowness) at >/=2

143 ing this analysis with viral replication and weight loss findings, we identified A/mallard/Portugal/7

144 tosan suppressed the respiratory rate, fresh weight loss, firmness and skin color with delay in the d

145 ted the first randomized trial of behavioral weight loss for HIV-infected patients (n = 40).

146 ORMS was significantly smaller in the 5%-10% weight loss group (1.6; 95% confidence interval [CI]: 1.

147 Individuals from the weight-loss group followed a calorie-restricted diet for

148 the control group, FMD did not change in the weight-loss group, but carotid-to-femoral pulse wave vel

149 on of the subscores was compared between the weight loss groups by using multivariable logistic regre

150 n who had stable weight (+/- 5%), women with weight loss had a significantly lower endometrial cancer

151 (i.e., nonsmokers without disease-associated weight loss), having central adiposity and a BMI corresp

152 rm of leishmaniasis, characterized by fever, weight loss, hepatosplenomegaly, and lymphadenopathy.

153 strongest among obese women with intentional weight loss (HR, 0.44; 95% CI, 0.25 to 0.78).

154 No weight loss, human malignancies, or systemic graft-versu

155 consists of lifestyle management, including weight loss if overweight or obese, a Dietary Approaches

156 sease (HD), but it is unknown to what extent weight loss impacts the rate of disease progression.

157 Weight loss improves almost all obesity-related co-morbi

158 used the smartphone application experienced weight loss in a significant way (80.39%, p-value < 0.00

159 Among those with 3-9% initial weight loss in both cohorts, 9 of 28 comparisons were co

160 gastrectomy, produce significant and durable weight loss in both humans and rodents.

161 easing GDF15 levels in serum correlated with weight loss in individuals with advanced prostate cancer

162 m a lethal challenge with H1N1 and prevented weight loss in infected animals.

163 Here we show that recombinant GDF15 induces weight loss in mice fed a high-fat diet and in nonhuman

164 and elevated levels are associated with body weight loss in numerous chronic human diseases.

165 tabolic and bariatric surgery (MBS) leads to weight loss in obese individuals and reduces comorbiditi

166 These findings should motivate programs for weight loss in obese postmenopausal women.

167 Conclusion Intentional weight loss in postmenopausal women is associated with a

168 balance and the mechanisms acting to resist weight loss in the context of static, settling point, an

169 There was also significantly greater weight loss in the liraglutide group than in the placebo

170 Maintaining weight losses in the long term remains the biggest chall

171 ed the intestinal microbiota associated with weight loss, increase in the vasodilator NO, and decreas

172 In this review we focus on the weight-loss independent effects of bariatric surgery, wh

173 ucceeds in reproducing literature documented weight loss-induced increments in human blood PLOP conce

174 Weight loss intentionality was assessed via self-report

175 ity and mortality could be reduced through a weight loss intervention among people with type 2 diabet

176 le examines the effects of Moving Forward, a weight loss intervention for African American breast can

177 d changes to hepatic complications by simple weight loss intervention without persistent reprograming

178 Furthermore, weight-loss intervention by bariatric surgery partially

179 e studied the effects of a diet and exercise weight-loss intervention on skeletal muscle (SM) mass an

180 The effect of a weight-loss intervention on the masses of lean tissues a

181 Weight loss interventions among breast cancer survivors

182 Weight regain after successful weight loss interventions is common.

183 Lifestyle-based weight loss interventions with 26 or more hours of inter

184 which outcomes could be preventable through weight loss interventions.

185 eous treatment effects (HTEs) from intensive weight loss interventions.

186 After controlling for weight loss, IPF and EPF volume reduction paralleled cha

187 Unintended weight loss is a hallmark of Huntington disease (HD), bu

188 Weight loss is also associated with a changing dietary m

189 rgy balance are dynamically interrelated and weight loss is resisted by counterbalancing physiologica

190 l weight maintenance after lifestyle-induced weight loss, it is critical to develop approaches that d

191 te infection correlated with high mortality, weight loss, liver pathology, and expression of viral pr

192 In multivariate models further adjusted for weight loss, losing VAT or intrahepatic fat was independ

193 llel, randomized trial stratified by initial weight loss (<10 kg vs. >/=10 kg), conducted from 20 Aug

194 velop approaches that distinguish successful weight-loss maintainers from regainers.The aim of this s

195 To establish the efficacy of a weight loss maintenance program compared with usual care

196 ht regain, the Guidelines recommend a 1-year weight loss maintenance program that includes at least m

197 weeks), and structured support for long-term weight loss maintenance.

198 LED compared with daily meal replacements on weight-loss maintenance and number of knee replacements

199 replacements or intermittent LED resulted in weight-loss maintenance for 3 y.

200 oarthritis, but the role of LED in long-term weight-loss maintenance is unclear.We aimed to determine

201 ity causes frailty in older adults; however, weight loss might accelerate age-related loss of muscle

202 IGS, amplifying radiation-induced mortality, weight loss, mucosal bleeding, debilitation, and intesti

203 esence of haemoptysis, fever, chronic cough, weight loss, night sweats, and poor appetite).

204 th follow-up with a mean difference in child weight loss of 0.001 (95% CI, -0.06 to 0.06).

205 e intervention trial and achieved an average weight loss of 10.5 kg (10% of initial body weight).

206 At 12 months, we recorded weight loss of 15 kg or more in 36 (24%) participants in

207 Co-primary outcomes were weight loss of 15 kg or more, and remission of diabetes,

208 The 18-mo moderate weight loss of 3.7 kg was similar in both groups, but th

209 ) weight loss of more than 10% (n = 82), (b) weight loss of 5%-10% (n = 238), or (c) stable weight (n

210 Mean excess weight loss of 5.9% +/- 2.4 and 9.0% +/- 4.1 was noted a

211 n (HOMA-B) were measured after a mean +/- SD weight loss of 6.8 +/- 3.4 kg over 10 wk and analyzed ac

212 A mean excess weight loss of 84% was achieved 12 months after DS.

213 Thermogravimetric analysis showed a weight loss of 85.81+/-0.52% and a decomposition tempera

214 oarthritis, categorized into groups with (a) weight loss of more than 10% (n = 82), (b) weight loss o

215 e status 70 to 100, and 6-month prediagnosis weight loss of no more than 10%.

216 week 30, 0.5 and 1.0 mg semaglutide achieved weight losses of 3.47 kg (95% CI 3.00-3.93) and 5.17 kg

217 plant candidates, but the effect of surgical weight loss on posttransplantation outcomes is unknown.

218 study was to examine effects of diet-induced weight loss on various vascular function markers and dif

219 Many trials assessing effects of dietary weight loss on vascular function have been performed wit

220 suppression of FGF21 was independent of body weight loss or improved hepatic insulin sensitivity and

221 radiation of the intestine did not cause any weight loss or lethality.

222 is progressively acquired but persists after weight loss or transplantation into a normal environment

223 re flexible endoscopy for the indications of weight loss or treatment of glucose intolerance (from pr

224 malabsorption if they had chronic diarrhea, weight loss (or insufficient gain), growth failure, or a

225 chest pain, nausea, vomiting, unintentional weight loss, or recent trauma.

226 etrics, and to explore putative mediators of weight loss outcomes.

227 ulted in a statistically significant greater weight loss over 12 months.

228 r PBT is similarly effective as FBT on child weight loss over 24 months.

229 ntly greater in participants who experienced weight loss over 4 y (HR: 2.21; 95% CI: 1.32, 3.71) and/

230 ing Roux-en-Y gastric bypass had substantial weight loss over 5 years, alongside improvements in como

231 esity-related comorbid disease and sustained weight loss over a 5-year period.

232 = 0.03) and FFM expressed as a percentage of weight loss (P < 0.001) than women in the CR group.Two y

233 Independent of weight loss, PA(+) with either diet had a significantly

234 loss and several secondary outcomes (parent weight loss, parent and child energy intake, and parent

235 ly altered by lifestyle interventions but by weight loss per se.

236 Weight loss, performance status (PS), C-reactive protein

237 nd behavior modification, in both the active weight loss phase and the long-term maintenance phase.

238 of an obesity paradox, there are benefits of weight loss, physical activity/exercise training, and in

239 Of the methods tested, weight loss plus combined aerobic and resistance exercis

240 atients with poor performance, more than 10% weight loss, poor lung function, and/or oxygen dependenc

241 ution saturated with CO2 was evaluated using weight loss, potentiodynamic polarization, electrochemic

242 ram plus a 12-month primarily internet-based weight loss program (intervention group), including a we

243 w-income postpartum women, an internet-based weight loss program in addition to the Special Supplemen

244 To test whether an internet-based weight loss program in addition to the Special Supplemen

245 st-guided (n = 125) or self-guided (n = 121) weight loss program supporting behavioral changes to pro

246 ians should use EBTs as part of a structured weight loss program that includes dietary intervention,

247 eir condition before enrolling patients in a weight loss program that includes EBTs.

248 of body weight during a 16-week, group-based weight loss program.

249 duction program to test whether an effective weight-loss program improves gut barrier function and wh

250 examine the effect of exercise training in a weight-loss program on asthma control, quality of life,

251 Adding exercise to a short-term weight-loss program should be considered as a useful str

252 ity, referral to this open-group behavioural weight-loss programme for at least 12 weeks is more effe

253 Mandibular advancement devices (MADs) and weight loss programs were also associated with reduced A

254 xpressed almost exclusively in CNS, and have weight-loss-promoting capabilities.

255 ostinfection (p.i.) and had markedly reduced weight loss, pulmonary inflammatory cell infiltration, m

256 SG and LRYGB are equally efficient regarding weight loss, quality of life, and complications up to 3

257 sis that reducing dietary BCAAs will promote weight loss, reduce adiposity, and improve blood glucose

258 weight/obese patients with cirrhosis, and if weight loss reduces portal pressure in this setting, is

259 ely among those with 3-9% and >/=10% initial weight loss.Regainers had higher body weight at year 4 t

260 leeve gastrectomy (VSG) produces sustainable weight loss, remission of type 2 diabetes (T2D), and imp

261 al signs of parkinsonism, depression/apathy, weight loss, respiratory symptoms, mutations in the DCTN

262 ing 17 MBq (213)Bi-IMP288 showed significant weight loss, resulting in a median survival of only 24 d

263 +) mice permits hyperphagia that counteracts weight loss, revealing a role for these neurons in a 'no

264 The secondary end points included short-term weight loss, serum obesity-related hormone levels, hunge

265 tenuated cisplatin-induced anorexia and body weight loss significantly.

266 tenuated cisplatin-induced anorexia and body weight loss significantly.

267 ion from 5 to 11 weeks of age prevented body weight loss, skeletal muscle atrophy, muscle weakness, c

268 Exercise is a common component of weight loss strategies, yet exercise programs are associ

269 007).Moderate but persistent dietary-induced weight loss substantially decreased both IPF and EPF vol

270 g adherence is the most important factor for weight loss success, and this is enhanced by regular pro

271 as potential long-term benefits and risks of weight loss surgery for patient subgroups, are discussed

272 and a general internist, discuss the role of weight loss surgery versus dietary and lifestyle modific

273 In abdominally obese men, dietary weight loss targeting a waist circumference of <102 cm i

274 side-effect profiles but all provide greater weight loss than do lifestyle changes alone.

275 Liraglutide induced greater weight loss than placebo at week 160 (-6.1 [SD 7.3] vs -

276 ncome postpartum women could produce greater weight loss than the WIC program alone over 12 months.

277 treatment reach but usually produce smaller weight losses than in-person interventions.

278 al circuit driving pathological anorexia and weight loss that accompanies chemotherapy treatment.

279 eatment alone typically produces only modest weight loss that is difficult to sustain.

280 at cancers despite accompanying anorexia and weight loss that may limit treatment adherence and reduc

281 variant and glucose-metabolism traits during weight loss.The rs1440581 PPM1K genetic variant was geno

282 Such studies may yield druggable targets for weight loss therapies.

283 cations appear to be successful in achieving weight loss, though the durability of these intervention

284 Family-based weight loss treatment (FBT) is considered the gold-stand

285 following a 4-month family-based behavioral weight loss treatment (FBT), of 2 doses (HIGH or LOW) of

286 tudy to consider oxytocin as a neurohormonal weight loss treatment.

287 nalyzed the effect of weather on intentional weight loss using global-scale data provided by smartpho

288 application in populations with high initial weight-loss variations.

289 By combining data on weight loss, viral replication, and the cross-reactive a

290 Greater weight loss was a positive prognostic factor, whereas in

291 Greater weight loss was achieved in men and women who favored pr

292 Whereas final moderate weight loss was indifferent, exercise attenuated the wai

293 ntervention, approximately 50% of CR-induced weight loss was maintained 2 y later, which was probably

294 required for cisplatin-induced anorexia and weight loss, we inhibited these neurons chemogenetically

295 Mean and percentage of weight loss were greater in the guided versus self-guide

296 e been unsuccessful in losing or maintaining weight loss with lifestyle interventions.

297 Purpose To investigate the association of weight loss with progression of cartilage changes at mag

298 Despite rapid and persistent weight loss with tolvaptan compared with placebo, in pat

299 High-protein diets increase weight loss (WL) during energy restriction; therefore, i

300 Weight loss (WL) is often followed by weight regain afte